Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Neurological Injury

Ketamine for Neurological Injury

4 papers and 11 clinical trials exploring ketamine as a treatment for neurological injury.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
IndicationApproximately 15 million individuals experience a stroke annually, while traumatic brain injuries occur in around 69 million people worldwide each year.

Neurological Injury

Neurological injury encompasses various forms of brain damage resulting from trauma, strokes, or other factors, leading to significant functional impairment. Recent research into psychedelic compounds presents promising avenues for innovative therapeutic interventions aimed at enhancing recovery and alleviating associated psychological conditions such as PTSD and depression.

Full Neurological Injury profile

Academic Research

4 papers
Open Accessindividual

Outcomes and physiologic responses associated with ketamine administration after traumatic brain injury in the United States and Canada: a retrospective analysis

Ketamine administration after traumatic brain injury was not associated with increased mortality or greater disability despite being given to more severely injured patients. Ketamine exposure correlated with fewer episodes of elevated intracranial pressure and smaller rises in TBI protein biomarkers, but a higher incidence of seizures and, in the intracranial haemorrhage subgroup, more cardiac events.

Published
December 31, 2023
Journal
Journal of Trauma Injury Infection and Critical Care
Authors
Peters, A. J., Khan, S. A., Koike, S., Rowell, S., Schreiber, M.
Open Accessmeta

Distributed harmonic patterns of structure-function dependence orchestrate human consciousness

Decomposing fMRI into connectome harmonics, the authors show that multi-scale structure–function coupling is a generalisable marker of consciousness: it increases during loss of consciousness (anaesthesia or brain injury)—distinguishing behaviourally indistinguishable patient subgroups and indexing covert consciousness—while LSD and ketamine produce the opposite decoupling that correlates with physiological and subjective measures.

Published
January 28, 2023
Journal
Communications Biology
Authors
Luppi, A. I., Vohryzek, J., Kringelbach, M. L., Mediano, P. A. M., Craig, M. M., Adapa, R., Carhart-Harris, R. L., Roseman, L., Pappas, I., Peattie, A. R. D., Manktelow, A. E., Sahakian, B. J., Finoia, P., Williams, G. B., Allanson, J., Pickard, J. D., Menon, D. K., Atasoy, S., Stamatakis, E. A.
Paywallmeta

Nonanesthetic Effects of Ketamine: A Review Article

This review (2018) examines (preliminary) evidence of the medical benefits of the non-anesthetic effects of ketamine, as well as supporting evidence of the effectiveness and tolerability of ketamine for improving pain conditions, depression, memory function in Alzheimer's disease, and brain damage after stroke. It also examines underlying mechanisms that exert these effects by stimulating or blocking certain neuroreceptor pathways.

Published
December 1, 2018
Journal
American Journal of Medicine
Authors
Eldufani, J., Nekoui, A., Blaise, G.
Open Accessindividual

A retrospective study of ketamine administration and the development of acute or post-traumatic stress disorder in 274 war-wounded soldiers

In a retrospective analysis of 274 surviving war‑wounded soldiers from Afghanistan, ketamine administration was not independently associated with development of acute or post‑traumatic stress disorder; multivariable regression identified only acute stress disorder and total number of surgical procedures as independent predictors of PTSD. Although a higher proportion of PTSD cases had received ketamine on unadjusted analysis, injury severity and other covariables accounted for that association.

Published
October 3, 2017
Journal
Anaesthesia
Authors
Mion, G., Masson, J. L., Granier, C., Hoffmann, C.

Clinical Trials

11 trials
RecruitingPhase II

Ketamine, SGB and Combination Treatment for TBI

This randomised, double-blind, placebo-controlled trial (n=175) will investigate the efficacy of stellate ganglion block (SGB) and ketamine infusion, both separately and in combination, in treating PTSD and TBI-associated headache.

Started
February 15, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06608277
Temporarily not availablePhase IV

Ketamine for Sedation in Severe Traumatic Brain Injury (Ketamine)

This open-label randomized trial (n=50) will assess the safety of ketamine plus propofol sedation versus standard-of-care analgosedation in ICU patients with severe TBI.

Started
June 1, 2024
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT06429657
Not yet recruitingPhase II

Ketamine Treatment for PTSD and MDD in TBI

Randomised, quadruple-blind, parallel Phase II trial (n=40) comparing IV ketamine 0.5 mg/kg vs midazolam 0.045 mg/kg twice weekly for 3 weeks in Veterans with mild–moderate TBI and comorbid PTSD and MDD to evaluate efficacy and safety.

Started
March 1, 2024
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06228391
RecruitingPhase I

Ketamine in Severe Traumatic Brain Injury

This early Phase I interventional trial (n=10) will assess the neurophysiological effect of ketamine in patients with severe Traumatic Brain Injury (TBI).

Started
February 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06062628
Unknown statusPhase NA

Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort

This observational cohort study (n=20) aims to investigate the impact of a combined protocol of subanesthetic ketamine infusions (SKI) and bilateral cervical sympathetic blocks (CSB) on ageing in Special Operations Forces (SOF) members undergoing treatment for PTSD/TBI.

Started
July 5, 2023
Type
observational
Randomized
No
Registry ID
NCT05855876
CompletedPhase III

Ketamine Low-dose Evaluation on Morphine Consumption in Traumatic Patients (KLOE)

This Phase III interventional trial (n=140) evaluates whether continuous low-dose ketamine infusion reduces morphine consumption by ≥25% at 48 hours in severe trauma patients versus placebo.

Started
August 5, 2022
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04833816

Explore further

Search all Ketamine papers Search all Neurological Injury trials Full Ketamine profile Full Neurological Injury profile